AstraZeneca launches Breztri in USA asthma after FDA approval

21 July 2026

Anglo-Swedish pharma major AstraZeneca (LSE: AZN) has launched Breztri Aerosphere [budesonide/glycopyrrolate/formoterol fumarate] in the USA for the maintenance treatment of asthma in patients aged 12 years and older.

The rollout follows the US Food and Drug Administration's (FDA) April 28, 2026 approval of the expanded indication, adding asthma to Breztri’s existing use in chronic obstructive pulmonary disease (COPD). AstraZeneca says the product is the first and only fixed-dose triple-combination maintenance therapy approved in the USA for this asthma population.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK